Exelixis restructures contract with Swedish Orphan

• Exelixis (NASDAQ:EXEL +1.9%) extends and refines its agreement with Swedish Orphan Biovitrum AB to support the distribution and commercialization of Cometriq (cabozantinib) for metastatic medullary thyroid cancer in the EU, Switzerland, Norway, Russia and Turkey.
• The new agreement, in effect until December 31, 2019, replaces the fixed fee structure with a sales margin-based scheme.